Immunovant, Inc. filed an 8-K with the U.S. Securities and Exchange Commission on September 3, 2026, reporting the voting outcomes from its 2026 Annual Meeting of Stockholders held on September 2, 2026.

Key Highlights

  • Quorum: 198,373,370 shares of common stock and Series A preferred stock were represented at the Annual Meeting, approximately 96% of shares entitled to vote.
  • Directors elected: Jacob Bauer, Douglas Hughes, and Robert Susman were each elected to the Board to serve until the 2027 Annual Meeting.
  • Auditor ratified: Ernst & Young LLP was ratified as independent registered public accounting firm for the fiscal year ending March 31, 2027, with 198,148,265 votes for.
  • Executive compensation: Named executive officer compensation was approved on a non-binding advisory basis, with 180,772,822 votes for and 8,437,839 votes against.
  • Proxy statement: A detailed description of each proposal was filed with the SEC on July 22, 2026.

Immunovant 2026 Annual Meeting: Director Elections and Key Vote Tallies

According to the filing, Immunovant, Inc. (NASDAQ:IMVT) convened its 2026 Annual Meeting of Stockholders on September 2, 2026, with approximately 96% of eligible shares represented. Stockholders voted on three proposals, the results of which were reported under Item 5.07 of the 8-K.

For Proposal 1, the election of directors, all three nominees were elected to serve until the 2027 Annual Meeting. Robert Susman received the highest support with 181,604,476 votes for and 7,698,088 votes withheld. Douglas Hughes received 174,053,304 votes for and 15,249,260 withheld. Jacob Bauer received 162,872,114 votes for and 26,430,450 withheld. Broker non-votes for each nominee totaled 9,070,806, according to the filing.

Proposal 2, the ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending March 31, 2027, passed with 198,148,265 votes for, 187,390 votes against, and 37,715 abstentions. Proposal 3, the non-binding advisory vote on named executive officer compensation, received 180,772,822 votes for, 8,437,839 votes against, 91,903 abstentions, and 9,070,806 broker non-votes, the filing disclosed.

What Was Disclosed

Immunovant filed an 8-K disclosing the vote tallies from its September 2, 2026 Annual Meeting, covering director elections, auditor ratification, and a non-binding advisory vote on executive compensation, with all three proposals receiving stockholder approval.